^
Association details:
| Biomarker: | EGFR L858R + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + BX795 (PDK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5354 - 3-phosphoinositide-dependent kinase-1 (PDK1, PDPK1) is a driver of osimertinib acquired resistance in EGFR mutant NSCLC
Published date:
03/09/2022
Excerpt:
We developed osimertinib-acquired resistant H1975-OSIR (T790M/L858R mutant) isogenic cells...In-vivo inhibition of PDK1 by treating mice with BX-795 in both H1975-OSIR xenografts and TC386-OSIR PDXs significantly enhanced the antitumor activity of osimertinib.
